Inventiva (NASDAQ:IVA) Reaches New 52-Week High – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $6.55 and last traded at $6.49, with a volume of 85139 shares changing hands. The stock had previously closed at $6.30.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IVA. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Piper Sandler began coverage on Inventiva in a research report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Saturday, September 27th. HC Wainwright began coverage on Inventiva in a research report on Wednesday, September 3rd. They set a “buy” rating and a $20.00 target price for the company. Finally, Guggenheim upped their target price on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

Inventiva Trading Up 3.7%

The firm has a 50-day moving average of $4.90 and a two-hundred day moving average of $3.85.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.